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I. Introduction to TB: 
Tuberculosis (TB) as a human health problem has been ubiquitous throughout 
history. In Northern Africa, evidence has been found that tuberculosis was present 
(although not a serious epidemic) in the pre-dynastic period (3000 B.C.E.). As people 
congregated more and more into large crowded cities its reach and grasp extended until 
it was responsible for one out of four deaths in 17th century Europe and was referred to 
as "The Great White Plague." Today, despite the advances of technology, drug 
treatments, and the insights offered by genetic screening, during this decade alone nearly 
90 million new cases of tuberculosis will occur and 30 million people will die from this 
disease. In a disturbing counterpoint to the global prevalence of tuberculosis, the TB 
infection rate that had been slowly declining in the US since 1953, took a disturbing turn 
in 1985 and has been increasing slowly ever since (Bloom, 1994) . To understand a 
disease and the equilibrium it reaches in a community, one must first understand its life 
cycle and general characteristics. 
Tuberculosis is an infectious disease, usually of the lower respiratory system (but 
with an ability to disseminate and settle in many different organs and tissues) and is 
caused by Mycobacterium tuberculosis, an obligate aerobe, rod shaped, and acid fast 
bacterium. The rods form filaments and appear moldlike in liquid medium, which earned 
the bacterium the genus name Mycobacterium (myco meaning fungus). The acid-fast 
quality of the tuberculosis bacterium is significant to the virulence of the organism; an acid 
fast bacterium has a large amount of lipid in the cell membrane and is thus resistant to 
desiccation and other stresses (including some antimicrobials). (Lansing, et. al., 1996) 
The life cycle the tuberculosis bacilli in the human body follows a consistent pattern. 
The disease is most often acquired by inhaling bacilli in the air. Once it reaches the lungs, 
the bacilli is usually phagocytized by macrophages. In a healthy individual the 
macrophages destroy the bacilli, in an unhealthy or immune compromised individual the 
bacilli often survive and the "host" macrophage then serves as protection from antibodies 
and allows the bacilli to reproduce undisturbed. The infected macrophages tend to 
aggregate forming the precursor to the "tubercle" (which gave the disease its name). As 
other macrophages respond to this tubercle, they usually are ineffective in destroying it 
either partially or entirely and in the process release cytokines that cause lung 
inflammation. Meanwhile in the center of the tubercle macrophages die leaving a 
cheeselike paste of bacilli, the tubercle then calcifies and can show up on X-rays. At this 
point, nature works in favor of the host, the aerobic bacilli are trapped in the center of the 
tubercle and can become inactive or dormant for years. However, depending on the state 
of the immune system and the characteristics of the individual the tubercle may also 
enlarge and become more fluid (in a process known unsurprisingly as liquefaction) and 
form an air filled cavity that the bacteria can reproduce in. Eventually the tubercles rupture 
and the bacilli can be disseminated into the airways of the respiratory system (allowing 
droplets of bacterium to be coughed up and making the disease highly contagious) and 
also enter the circulatory and lymphatic systems. (Lansing et. al. 1996) 
Detection and monitoring of the disease from an epidemiological standpoint can be 
difficult because of the extended stage of dormancy. It is estimated that up to a third of the 
worlds population may be infected with the bacilli, but many may not ever know, or may 
only show limited symptoms. On an individual level though, a tuberculin skin test is an 
easy, relatively painless way to detect an infection. The test involves a small cutaneous 
injection with a purified protein derivative (PPD) of the tuberculosis bacterium, cell-
mediated immunity in infected individuals causes reddening or hardening in the area in the 
next few days indicating a positive test. The test does have some drawbacks, a 
vaccination history or a previous infection can cause a positive skin test as well. A sputum 
sample (testing for acid fastness and/or viewing directly by fluorescence microscopy) is a 
more reliable but a technically more involved and time consuming process. The most 
common type of assay begins with the introduction of DNA with specific marker genes into 
a culture taken from a person thought to be infected, colonies are grown from the 
transformed bacteria and the marker gene is selected or tested for. This is a common 
diagnostic tool for many kinds of bacterium, however, TB has the characteristic of being 
one of the slowest of the slow-growth microbes and it can take two to three weeks for 
colonies to appear from cultures. This makes diagnosis, strain identification, and research 
done with TB a time consuming process at best (Taylor, 1999) 
It should be mentioned in passing that although tuberculosis most often settles in 
the lower respiratory system (Pulmonary Tuberculosis), a small number of infections occur 
primarily in other systems in the body each following the same general trend, but with 
unique repercussions. This occurrence is especially evident in immune compromised 
people such as those with HIV. Among HIV patients, a full 15% of reported Tuberculosis 
cases are considered extrapulmonary and present diagnostic difficulties (the usual method 
of definitive diagnosis requires a sputum sample). Also, if host defenses are weakened 
by other diseases, the immune system cannot contain the disease and it spreads to other 
organs (Miliary or Disseminated Tuberculosis). The organs and systems most often 
effected by miliary tuberculosis are the lungs, liver, bone marrow, kidneys, adrenals and 
spleen. The study of the course of infection in extrapulmonary and miliary tuberculosis is 
a specialty in itself and will not be examined here except as a side note. Also, other 
species of Mycobacterium exist that are infectious to humans to a more limited extent. M. 
bovis and M. avium are two that can be serious problems in individuals with depressed or 
non-functioning immune systems. M. Avium will be focused on in section Ill of this work. 
Vaccines for tuberculosis have been in use since the 1920's, the BCG vaccine is the 
most well known (Bacillus of Calmette and Guerin, named for the scientists who originally 
isolated the strain). The bacillus in the vaccine was derived from a strain of Mycobacterium 
Tuberculosis Bovis that has been rendered antivirulent, worldwide it is considered very 
effective and it is estimated that 70% of the world's schoolchildren received it in 1990. 
However, its is less widely used in the United States as it causes all subsequent skin tests 
to come up positive and is only administered to "high risk" children. 
Tuberculosis rates actually began to decline before effective treatments or the BCG 
vaccine was introduced, likely because of the recognition of the transmission abilities of the 
disease and the segregation of infected patients in sanatoria. Another outside factor that 
lowered the incidence of disease was the pasteurization of milk (reducing the transmission 
of bovine Tuberculosis to humans). However, perhaps the largest factor contributing to the 
pre-vaccine decline in Tuberculosis rates was a socioeconomic one, in the early 1900's 
living conditions began to get steadily better eliminating the enclosed environment, poor 
ventilation and overcrowding that was optimal for Tuberculosis spread (Bloom, 1994). 
Since then, the vaccine, antimicrobial and the introduction of chemotherapy as a treatment 
further hastened the decline of the disease. 
A number of factors had obviously been working steadily since the early 20th 
century in industrialized countries to reduce the incidence of tuberculosis, but around 1985 
the trend leveled out and began to reverse itself slowly. The best way to account for this 
resurgence in tuberculosis is a combination of overuse/misuse of antibiotics, causing 
antibiotic resistant strains to arise, as well as the growing epidemic of AIDS which gives 
tuberculosis a window of opportunity to re-establish itself (Taylor 1999). HIV is probably 
the largest factor in tipping the equilibrium that exists between human controls and disease 
virulence back in favor of the microbes. (See figures 1-2) Worldwide, the resurgence of 
TB (as well as the emergence of antibiotic resistant strains) has been consistent from 
country to country, for much the same reasons: decreased use of the vaccine, the spread 
and increase of HIV related infections, lower case detection, or incomplete or poorly 
managed courses of therapy (Netto et. al, 1999). (See figure 3). 
On an individual patient level, the initial treatment of Tuberculosis generally is some 
combination of four drugs: isoniazid, rifampin, streptomycin and ethambutol. Of these 
four, either rifampin or isoniazid are always used for treatment, generally in combination 
with one or two of the others to shorten the duration of therapy. Today, strains of 
tuberculosis have been found that are resistant to one, a combination of two or three, or 
all of the four first line drugs. These strains become resistant by natural mutations, 
noncompliance with prescribed therapy, or an inadequate treatment process. Resistant 
strains extend the duration of therapy from six to more then 24 months and cause a lower 
overall cure rate (Taylor, 1999). 
Tuberculosis research keeps expanding its reach on par with the expansion of the 
disease, labs across the country and around the world concentrate a large part of their 
research to the genetic basis of antibiotic resistance, and towards developing quicker, 
easier diagnostic tests for the disease. However, when looking to the future, some issues 
in research and treatments stick out as problematic or relevant. First, the constant 
epidemiological problems with identifying just who and how many people have the disease, 
this is a difficult problem to overcome since the number of those infected (but 
asymptomatic) is two orders of magnitude larger then those who actually show signs of 
disease. Additionally, cross-reactivity with the BCG vaccine creates another dimension 
of complexity in testing for the disease. The vaccine itself is another source of controversy 
within the scientific community, it is the most widely used vaccine of all times, yet its true 
effectiveness remains in doubt (many have argued that its effectiveness is highly 
contingent upon other environmental factors, and this is currently being researched as 
well) . Another problem is that isoniazid, one of the primary drugs for treating tuberculosis 
has come under surveillance and being ineffective at preventing long term reinfection as 
well as having other adverse complications when administered to people with other health 
problems such as hepatitis or some form of immune compromise (Bloom, 1994). New 
drugs and novel combinations of drugs are a hot area in current research 
Despite the volumes we know about tuberculosis, the disease remains a huge 
health problem in the world today. The research examining tuberculosis is as diverse as 
the manifestations of the disease, and much more is left to be discovered in all of the 
aspects of research before it can truly be considered a disease under control. For better 
or worse, human history and tuberculosis are still an unbreakable pair. 
Research Project 1 : Resistance of Mycobacterium 
tuberculosis to Ethambutol. MIC determination using 
the Etest Method (AB Biodisk, Sweden). 
A. General background of the project. 
In a recent study of tuberculosis cases in Texas it was found that while the incidence 
of tuberculosis is fairly low (compared to developing countries), of the cases reported, 
almost 10% were resistant to at least one of the four first line drugs (Taylor, 1999). When 
tuberculosis is diagnosed in a patient, especially one who may have contracted an 
antibiotic resistant strain, discovery of the type and extent of the resistance is imperative 
to a successful treatment regimen. For years, BACTEC (a broth dilution method, where 
a microbe is incubated in serial dilutions of an antibiotic to see what is the minimum 
concentration that prohibits growth-- called a Minimum Inhibitory Concentration, or MIC) 
has been used, along with similar agar dilution methods for determining the resistance or 
susceptibility of strains for certain drugs. However, most of these methods are fairly costly, 
requiring specific machines to read concentrations of bacteria in broth; complicated, 
requiring multiple plates and dilutions to be kept track of; inaccurate, giving only a general 
ballpark MIC number; and simply cumbersome, requiring a great deal of lab equipment and 
glassware. With M. tuberculosis, there is the added complication of the 2-3 week time 
window required for full growth. A few alternatives for MIC determination have appeared 
recently including Etest (AB Biodisk, Sweden), a method that the lab I did research in this 
summer has helped to test and standardize. Etest simply is a strip of paper with a gradient 
of antibiotic dry-adhered to it that is placed on a plated lawn of bacteria. The antibiotic 
diffuses into the agar, creating an ellipse of inhibited bacterial growth. (See figures 5-6). 
The MIC can be read where the ellipse crosses the strip. Etest appears to be a simple 
alternative to many of the more unwieldy methods, taking less time (especially with M. 
Tuberculosis, some plates can be read in five days rather then three weeks) and in the 
case of ethambutol, MIC determination may actually be a more accurate method. 
Ethambutol is a bacteriostatic antibiotic (see figure 4) and has been found to be unstable 
in solution at common incubation temperatures and thus, may have shown a higher MIC 
(more resistant) for a strain then may have actually been true (e.g. since the antibiotic was 
actually already broken down, it didn't effect the bacteria which then appeared to have 
resistance to it). However, this had never been quantified, thus, the first research project 
that I selected was to use the Etest method on strains collected from local hospitals 
between 1991-96 (Mycobacterium stay alive preserved in glycerol and frozen indefinitely) 
that had been labeled as Ethambutol resistant to test for MIC in a new way. This 
experiment would hopefully establish which method was the most accurate in determining 
the actual resistance or susceptibility of a strain. 
B. Published Abstract 
Minimum Inhibitory Concentration determination of ethambutol for 
Mycobacterium tuberculosis using the Etest method. 
Marla A. DeWitt: University of Northern Iowa, Class of 2000 
Audrey Wanger, Ph.D. Department of Pathology 
U-T Houston Summer Research Program 
Key Words: Mycobacterium Tuberculosis, ethambutol, resistance, Etest, 
Minimum Inhibitory Concentration (MIC). 
In this study, clinical isolates of Mycobacterium tuberculosis labeled as ethambutol 
resistant were re-examined for accuracy of their MI Cs (Minimum Inhibitory Concentrations). 
Etest (AB Biodisk, Sweden) was used as an alternative to traditional methods of MIC 
determination such as BACTEC and agar dilution. The Etest is a paper strip with a 
graduated concentration of an antibiotic that is applied to an agar plate, the antibiotic 
diffuses into the agar and shows up as an ellipse of bacterial grown inhibition that crosses 
the strip at the MIC of the drug. Ethambutol is a bacteriostatic drug, one of the four first 
line drugs used to treat tuberculosis, and has been shown to be unstable in solution at 
incubation temperatures. It was hypothesized that strains of M. tuberculosis clinically 
collected between 1991-96 and labeled as resistant (MIC> 16µ1/ml) to ethambutol from the 
BACTEC method may have shown false resistance due to the breakdown of the drug in 
solution. To test this, the strains were suspended in 7H9 broth to a McFarland turbidity 
standard of 1.0 and swabbed onto an agar plate. An ATCC strain of M. tuberculosis known 
to be resistant to ethambutol was plated as a control. After a day of incubation, an 
ethambutol Etest strip was added. After seven days, the MIC was read (at 80% inhibition 
for bacteriostatic drugs). Of the nine strains labeled as resistant, seven were found to be 
susceptible, and two resistant. These findings suggest that Etest can be considered more 
reliable then microdilution methods in this case. 
Published in: Summer Research Program Student Abstracts 1999, Volume XI, University 
of Texas-Houston Health Science Center. 
C. Formal Lab report and Results 
Introduction: Since Tuberculosis began its climb in frequency of incidence in 1985, the 
need for quick, simple tests for antibiotic resistance has been growing proportionally. 
Some questions have risen about both the accuracy and precision of the BACTEC method 
for Minimum Inhibitory Concentration (MIC) determination. The stability of ethambutol (see 
Figure 4),a bacteriostatic drug used for first-line treatment of Tuberculosis, in solution at 
incubation temperatures has been shown to be inconsistent, thus a comparison of the 
relative susceptibility of nine strains of Mycobacterium tuberculosis (collected between 
1991-96) determined by BACTEC to be resistant to Ethambutol, and their susceptibilities 
as determined by Etest was made. 
Procedure: Note: All handling of M. Tuberculosis was done in accordance with Bio-Safety 
Level Ill precautions 
Nine strains of M. tuberculosis that were labeled as ethambutol resistant were 
'subbed' (removed from the frozen glycerol solution they were preserved in) and inoculated 
onto Lowenstein-Jensen agar slants. An ATCC (standard) strain that was known to be 
resistant was also inoculated onto an L-J agar slant. In two weeks, when colonies had 
formed, a few were pulled off the surface of the slant with an inoculating loop and 
suspended in 7H9 broth to a McFarland turbidity standard of 1.0 (if the colonies did not 
break up in the broth with simple vortexing, they were immersed in a sonicator for 30 
seconds). The solution was then swabbed onto a Middlebrook 7H11 agar plate with OADC 
enrichment and allowed to incubate at 35 °C for 24 hours. An ethambutol Etest strip 
containing a gradient of 0.016 to 256µg/ml was then added carefully to the surface of the 
plate and the plate was allowed to incubate until colonies formed and a clear ellipse of 
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Discussion: The data seem to show a large discrepancy between the BACTEC 
determination of MIC and the Etest method. Further study should be done on the relative 
stability of Ethambutol and the precision of the Etest method. However, for now it can be 
maintained that Etest is a better determinant of MIC determination for ethambutol. Since 
the ethambutol strips have been standardized for concentration , and used successfully and 
accurately on other bacteria, the sources of error were minimized. 
Research Project 2: Point Mutations of 
Mycobacterium Avium Contributing to Clarithromycin 
resistance 
A. Background and potential applications of this project. 
After the successful project with determining the MIC of strains of tuberculosis with 
ethambutol, I decided to look deeper into the genetic basis of antibiotic resistance in 
Mycobacterium. The next project I chose dealt with Mycobacterium Avium, (often referred 
to as MAC) a relative of tuberculosis and a growing problem as a blood infection in 
immunocompromised patients (such as those with HIV, or otherwise depressed immune 
systems). The point mutation that causes resistance to clarithromycin, a macrolide and 
an antibiotic often used for the treatment of MAC, has been suspected to be at positions 
cognate to E. Coli2058 and 2059 (positions 2143 and 2144 in MAC). Clarithromycin is 
a bactericidal drug that works by inhibiting protein synthesis by binding to the peptidyl 
transferase loop of 23S rRNA. It is hypothesized that these point mutations keep 
Clarithromycin from binding to this loop. 
M. Avium DNA has the added complication of being notoriously unstable and difficult 
to work with. It degenerates rapidly even if it is refrigerated, the cells can't be sonicated 
at all without extensive damage to the DNA, and even frozen DNA can't be thawed and 
refrozen more then once. Thus any actual testing and diagnosis of a strain as antibiotic 
resistant is difficult and time consuming. However, it was hoped that if the ELISA 
technique (Enzyme Linked lmmunosorbent Assay) could be adapted to work with M. avium 
DNA, it would yield a quick, simple test for antibiotic resistance. 
An ELISA assay is a heavily used technique in biotechnology. Essentially, it takes 
advantage of the specificity of either antibody-antigen or DNA-Complementary DNA 
binding to provide simple, easily readable tests for the identity of a substance. For MAC, 
the test was for whether the DNA sequence at positions 2143 and 2144 were wild type or 
a mutation. The starting point for the assay in this case was a 96 well microtiter plate 
coated with the universal 'catcher' streptavidin. A 490bp fragment of DNA from strains 
shown by Etest to be Clarithromycin resistant, and that included the potential point 
mutation was amplified. In four separate tubes, four different capture probes (Each with 
a different base at the mutation site: A, T, C or G) that were tagged with biotin at the 5' end 
were ligated with the DNA (see figure 8). Ideally, only the probe with the correct base pair 
sequence would 'stick' to the DNA. A reporter probe that would stick to all the DNA (no 
matter what the mutation) and was tailing labeled at the 3' end with digoxygenin and 
labeled at the 5' end with phosphate, was also ligated (see figure 9). At this point, each 
of the four tubes were added to separate wells in the microtiter plate. (See figure 10) The 
streptavidin coating would then catch the biotin tag at the end of the capture probe. Again, 
ideally, if the capture probe was the correct one for the mutation, the whole package would 
then also be attached to the plate (both the DNA in question and the reporter probe with 
the digoxygenin tag), and would not be rinsed away by subsequent washes. Finally, the 
plate was washed with and anti-digoxygenin alkaline phosphatase conjugate, then a 
substrate for the conjugate, and an amplifier to develop the color. If the capture probe-
DNA-reporter probe package was there, then there would be an obvious color change that 
could be read in a spectrometer as absorbance (a higher absorbance would correspond 
to higher resistance. Development of color would mean that the particular probe in that 
well was the one that corresponded to the DNA sequence, thus it would be possible to 
identify whether or not there was a mutation, and ultimately, whether or not the strain was 
Clarithromycin resistant. 
This, however, turned out to be the classic case of research gone awry. Results 
initially came back as completely negative, no color change at all for any of the probes. 
To attempt to fix this problem, pre-coated and standardized streptavidin plates were 
obtained (as opposed to coating our own). Results then came back as indeterminate and 
apparently random (e.g. identical samples done in triplicate would return absorbances with 
a ten-fold difference). Tailing digoxygenin labels were then substituted for end labeled to 
try and get better color development and results still came back indeterminate. With the 
assistance of Dr. Jeff Actor, an entirely new kind of tag was substituted for the digoxygenin 
that was read in opaque porcelain plates and emitted light when the conjugate was added. 
None of these techniques improved the data very much. 
Although this project did not return very good results, except possibly for the fact 
that ELISA is not a suitable assay for M. Avium. I decided to include it in my presentation 
and thesis anyway, since it is the project I learned the most from (and also the more 
interesting one) this summer. When a project doesn't work, the requirements for critical 
thinking and learning new lab technique are raised significantly. In fact, the most 
fundamental thing I learned this summer could be that research is not always about getting 
the answers you expect. 
B. Formal Lab Report and Results 
Introduction: Mycobacterium Avium is a pathogen of growing importance in clinical 
research. Its incidence as a disease in immunocompromised patients has been growing 
and a simple test for antibiotic resistance is needed. The mutation that causes 
clarithromycin resistance is believed to be found at positions cognate to E.Coli 2058 and 
2059 (MAC positions 2143 and 2144). Thus, in this experiment, using capture probes 
designed around this mutation, the ELISA method (Enzyme Linked lmmunosorbentAssay) 
was attempted as a shortcut method to determining macrolide resistance. Five Strains of 
MAC were found that exhibited clarithromycin resistance, a QC strain that was known to 
be susceptible was used as a positive control , and M. Abscessus and E.Coliwere used as 
negative controls. 
Procedure: 
Stock Solutions Needed: 
1. Tris-NaCl wash buffer (1 OOmM Tris-HCI [pH 7.5]; 150mM NaCl; 0.05% Tween 20) 
1.2 g Tris 
0.877g NaCl 
50µ1 Tween 20 
q.s. to 100ml with ddH20 
2. NaOH Wash Buffer (0.01 N NaOH; 0.05% Tween 20) 
1ml 1N NaOH 
50µ1 Tween 20 
q.s. to 100ml with ddH20 
3. Plate Blocking Buffer (PBB) (0.5% BSA [pH 7.0]) 
0.5g BSA 
q.s. to 100ml with 1 x PBS 
4. 0.1% Triton X-100 (100ml) 
0.1 ml Triton X-100 
q.s. to 100ml with ddH20 
5. Ligase reaction inhibitor (1 OOmM EDTA; 0.1 % Triton X-100) 
3.7g EDTA 
0.1 ml Triton X-100 
q.s. to 100ml with dd H20 




1 .44g Na2H PO 4 
Dissolve in 800ml H20 
Adjust pH to 7.0 
q.s. to 1000ml 
7. ELISA final wash buffer/ Positive control dilutent (TBS) (0.05M Tris-HCI [ph 7.5]; 
0.15M NaCl) 
1.51 g Tris 
2.19g NaCl 
230ml ddH20 
Adjust pH to 7.5 with 2M HCL 
q.s. to 250ml 
8. ELISA Stop Solution (0.3M H2S04) 
59ml ddH20 
1 ml Concentrated H2S04 
(Add acid to water) 
Pre experiment set-up: Primers, capture probes and reporter probes were obtained 
from Genosys and stock solution of 200µM was made from the primers, 1 OOµM solution 
was made from the capture and reporter probes. 
Strains of M. Avium with the potential to be Clarithromycin resistant were acquired 
and subbed onto Lowenstein-Jensen agar slants, after incubation, colonies were 
suspended and vortexed gently in solution that was adjusted to a McFarland turbidity 
standard of 3.0 and swabbed onto a 7H11 plate. An ATCC strain known to be susceptible 
were also plated along with E. Coli and M. Abscessus strains to be used as known 
resistants . A Clarithromycin Etest strip was added to each plate and after 5 days the MIC 
was read. The five resistant strains were selected for use in this experiment. 
DNA Extraction: 2 Mycobacterium Avium Complex (MAC) colonies were pulled off 
7H11 agar plates. The colonies were re-suspended in 1 OOµL of double distilled (dd) water 
in a 0.5ml microcetrifuge PCR tube. The tubes were heated at 99°C for 15-20 minutes 
and then spun briefly at 1 O,OOOrpm. The supernatant was removed to a new 
microcentrifuge tube and frozen. 
PCR Reaction: To amplify the extracted DNA, a 0.5ml PCR tube was prepared for 
each sample (with an extra one to use for a blank). 
In each tube: 
PCR Supermix 45µL 
Primer 1 ( 1 OµM) 1 µL 
Primer2(10µM) 1µL 
Template DNA (ligand) 3µL 
**(For blank, add 3µL ddH20) 
50µL Total 
Each tube was then layered with 30µL wax and placed in a thermocycler with the 









(Steps 2-4 repeat X39) 
72°C 1 O' Final Elongation 
4°C END 
**Potential stopping point, the PCR product can be stored indefinitely at 4 °G. 
Quick Check: (To insure the PCR worked), 
For Each PCR Sample, add to 0.5ml tube (in this order): 
9µ1TE 
1 µI PCR product 
1µ1Dye 
Each tube was then transferred into a well of a 0. 7% agarose gel made with 0.5x TE. 
The blank was also loaded in an adjacent well, along with a "A ladder marker lane. The gel 
was then run at 90V until the purple/blue band of the dye was 2/3 down the gel. The Gel 
was disconnected, stained in 100ml ddH20 and 1 OµI ethidium bromide for 15 minutes then 
destained in ddH20 for 15 minutes. A photo was taken under UV light and the samples 
were checked for product and contamination. 
Cleanup: The PCR product was then cleaned using the Promega "DNA Cleanup Kit" 
as per manufacturer's instructions. (This removes excess primers and bases left by the 
PCR reaction and the supermix used). 
Pre-ELISA: If microtiter plates were being prepared rather then purchased, a 96 well 
flat bottomed microtiter plate was obtained and 50µ1 of 25µg/ µI streptavidin in 1 xPBS (ph 
= 7.0) was added to each well. The plate was then incubated at 37°C for 1 hour. The 
streptavadin was then removed and the plates blotted face down on paper towels. 200µ1 
of blocking buffer was then added to each well and the plates were then incubated at room 
temperature until needed. 
Ligation: Triplicate tubes of each sample were done. A ligation mix was made as 
shown below: 
475µ1 ddH20 
120µ1 1 Ox Ligase buffer 
2µ1 Capture Probe 
2µ1 Reporter Probe 
.1..!Jl Ligase (5µM) 
600µ1 total 
In each triplicate tube, 1 OµI of the ligation mix was mixed with 1 OµI of diluted, cleaned PCR 
product (1 OµI clean PCR to 90µL 0.1 % Triton). Each tube was layered with 1 OµI of wax and 
placed in a thermocycler programmed for the following. 
93°C 30" 
58°C 5' 
Repeat steps 1-2 x9 
4°C End 
After the tubes were removed from the thermocycler, 10µ1 of 100mM EDTA/0.1% Triton 
x100 was immediately added to stop the reaction. 
Capture of 5' Biotinylated probe: The blocking buffer was removed from the microtiter 
plate and it was blotted face down on paper towels. 200µL Tris-NaCl wash buffer was then 
added and then blotted out of the plate as well. From each tube, all 30µL of the ligated 
mixture was added to each corresponding well. The plate was then incubated >30 minutes 
at room temperature. 
Detection of 3' Digoxygenin labeled probe: The plate was then washed twice with 
200µ1 NaOH buffer, then washed twice with 200µ1 of the Tris-NaCl buffer. The plates were 
blotted out and 30µ1 of the alkaline phosphatase conjugate was added to each well 
(excluding the last column which is reserved for the positive control). The plate was then 
incubated for 30 minutes at room temperature (the positve control was prepared during this 
time) and then washed five times with 200µ1 Tris-NaCl buffer. 
Positive Control: While the plate is incubating, 50µ1 of the positive control mix 
(included with the ELISA kit) was added to the first well of the last column, and 25µ1 of TBS 
was added to the remaining wells in the column. Using a micropipet and being careful not 
to scrape the bottom of the well, 25µ1 was transferred from the first well to the second, then 
the second to the third, etc. The last 25µ1 from the final well was discarded. 
ELISA Kit: After the final 30 minute incubation, 50µ1 of susbstrate was added to each 
well (including the positive controls). The plate was incubated for 15 minutes at room 
temperature, then 50µ1 of amplifier was added to each well (including positive controls). The 
plate was incubated for 15 minutes more and finally the reaction was stopped by adding 
50µ1 H2S04 to each well (including positive controls). The plate was then read for 
absorbance of developed color at 495nm in a spectrophotometer. 
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R-esults-for First MAC ELISA 7/6/99 
Overview 
fhis basic protocol is a starting point for creating your own protocol/ data files. This file 
contains the groups Standard, Unknowns, and Blank. (Additional groups can be added using 
New .. . from the template dialog group menu.) The Standards are plotted on a Standard Curve. 
The Unknowns are interpolated from the linear fit of the Standard Curve and the calculated 
concentrations are shown in the unknowns group table. 
This file can be modified and saved as a new protocol file for future use. From the File menu 
select Save As ... . In the "Save This Document As" type box, enter a name for the protocol file. 
Click on the Protocol File radio button. Choose Save. 
Assay type: 
Number of plates: 
Endpoint read at 405 nm. 
1 












Raw Data Reduction Parameters 
Wavelength combination: Ll 
Subtract plate blank: Off 
Data Dis12la~ 012tion 
Option: RawOD 
Pla t e # 1 
2 3 4 5 6 7 
0.045 0 .063 0.053 0 .012 0.057 0 .053 
0.052 0 .043 0 .057 -0 .002 0 .052 0.066 
0 .085 0 .070 0.058 0.016 0.062 0 .0 5 8 
0 .059 0.041 0 .057 -0 .008 0 .056 0 .062 
0 .084 0 .077 0 .050 -0.006 0.063 0 .085 
0 .061 0.079 0.052 -0 .007 0.055 0.059 
0.088 0 .060 0 .044 -0 .002 0.073 0 .062 
0 .061 0.057 0.060 -0.005 0.028 0. 043 
Plate Blank Subtracted L 1 = 0.05275 
8 1 0 1 1 
0.003 -0 .006 
0 .000 -0.003 
Calibrate On 
Plate Read: 
4:05 PM 7/6/99 
7/6/99 4:07 :31 PM MARLA 
Template for Second ELISA 
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0 . 106 
0 . 120 
0 . 126 
0 . 111 
0 .115 
0 . 103 
0 .077 
0 .020 
Results for Second ELISA 7/12/99 (Unstopp~d 
ligation) 
Plate#1 
2 3 4 5 6 7 8 9 10 1 1 12 
0 . 115 0.167 0 . 127 0 .124 0 .142 0 .241 0 .250 0 .242 
0 . 112 0 . 106 0 . 101 0.115 0 . 109 0 .135 0 .111 0 . 120 
Calibrate On 
0 . 116 0 .088 0 .077 0 .093 0 .084 0 .075 0 .083 0 .083 
0 .077 0 .080 0 .083 0 .068 0 .070 0.080 0 .074 0.095 
0 . 112 0.130 0 .476 0 .304 0 .526 0 .500 0 .549 0.575 -0 .010 
0 .077 0 .068 0 .023 0.019 0 .031 0 .030 0 .015 0 .019 -0 .023 -0 .005 
0 .068 0 .063 0.037 0 .031 0.031 0.045 0 .043 0.039 -0.010 -0 .005 
0.022 0 .014 0 .048 0 .038 0 .007 -0.002 0.118 0 .061 -0 .071 -0.022 
Plate Blank Subtracted L1 = 0.157666666666667 
Template·for Third-ELISA 
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Results for Third ELISA 7/14/99 (Stopped 
Ligation) 
Overview 
This basic protocol is a s tarting point for creating your own protocol/ data files. This file 
con ta ins the groups Standard, U_nknowns, and Blank. - (Additional groups can be added using 
New ... from the template dialog group menu.) The Standards are plotted-et1 a Standard Curve. 
The Unknowns are interpolated from the linear fit of the Standard Curve and the calculated 
concentrations are shown in the unknowns group table. 
This file can be modified and saved a~a new protocol file for future use. From the File menu 
select Save As .... In the "Save This Document As" type box, enter a name for the protocol file. 
Click on the Protocol File radio button. Choose Save. 
Assay type: 
Number of plates: 







Endpoint read at 405 nm. 
1 
Standard (in mg/ml), and Unknowns 
Endpoint 




Raw Data Reduction Parameters 
Wavelength combination: Ll 
Subtract plate blank: Off 
Data Dis12lai 012tion 
Option: Raw OD 
Plate#1 
2 3 4 5 6 7 8 9 1 0 1 1 1 2 
A 0 .005 0 .007 0.008 0 .014 0 .007 0 .007 0 .004 0 .047 
B 0 .025 0 .040 0 .038 0 .024 0 .018 0 .025 0.017 0.013 
Calibrate On 
C 0 .032 0 .030 0 .039 0.029 0 .024 0 .017 0 .009 0 .012 
D 0 .074 0 .097 0 .099 0 .028 0.025 0 .020 0.023 0.016 
E 0 .011 0.021 0 .013 0 .019 0.020 0 .008 0 .007 0.004 
F 0 .013 0 .021 0.028 0 .019 0.029 0.020 0.021 0 .028 
G 0 .075 0.043 0 .038 0 .015 0 .038 0.016 0.013 0 .030 0.016 
~ 0 .014 0 .042 0 .034 0 .024 0.021 0 .161 0 .013 0 .027 0.035 
Plate Blank Subtracted L 1 = 0.05325 
7/14/99 1:15 :13 PM MARLA Exp#3pl#1 
.--·-
Template for Fourth ELISA 
------- -- ------ -- - ---- ----------- -----
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Results for Fourth ELISA 7/22/99 (pre-coated 
plates and-tailing Digoxygenin label) 
Overview 
This basic protocol is a starting point for creating your own protocol/ data files. This file 
contains the groups Standard, Unknowns, and Blank. (Additional groups can be added using 
New ... from the template dialog group menu.) The Standards are plotted on a Standard Curve. 
The Unknowns are interpolated from the linear fit of the Standard Curve and the calculated 
concentrations are shown in the unknowns group table. 
This file can be modified and saved as a new protocol file for future use. From the File menu 
select Save As... . In the "Save This Document As" type box, enter a name for the protocol file. 
Click on the Protocol File radio button. Choose Save. 
Assay type: 
Number of plates: 
Endpoint read at 405 nm. 
1 












Raw Data Reduction Parameters 
Wavelength combination: Ll 
Subtract plate blank: Off 
Data Display Option 
Option: Raw OD 
Plate#1 
2 3 4 5 6 7 
A 0.010 
8 9 1 0 1 1 12 
• End oint 
---t---t-----+----1--- ---;- --1-----;1-L_1_4_9_5 ___ ---; 
B 0 .002 
C 0.015 
D -0 .001 
E 1 .495 
F 0 .126 
G 0.274 
-f 0.439 




---+---+--- -+----+----+---t-----t 11 :22 AM 7 /22/99 





Template for Sixth ELISA 
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A 
Results for Sixth ELISA (Triplicate samples are 
aliquoits from same tubes: results should be 
identical). 
This basic protocol is a starting point for creating your own protocol/ data files. This file 
contains the groups Standard, Unknowns, and Blank. (Additional groups can be added using 
New .. . from the template dialog group menu.) The Standards are plotted on a Standard Curve. 
The Unknowns are interpolated from the linear fit of the Standard Curve and the calculated 
concentrations are shown in the unknowns group table. 
This file can be modified and saved as a new protocol file for future use. From the File menu 
select Save As .... In the "Save This Document As" type box, enter a name for the protocol file. 
Click on the Protocol File radio button. Choose Save. 
Assay type: 
Number of plates: 
Endpoint read at 405 nm. 
1 












Raw Data Reduction Parameters 
Wavelength combination: Ll 
Subtract plate blank: Off 
Data Display Option 
Option: Raw OD 
Plate#1 
2 3 4 5 6 7 
0.000 -0.001 ,q.003 0.006 0.004 0.005 
8 9 1 0 
0.010 0.019 
1 1 1 2 
B 0.091 0.110 0.108 -0 .003 -0 .002 -0 .005 0.021 0.026 0.023 
C 0.077 0.087 0.084 0 .003 -0.003 -0.003 0.014 0.012 0.018 
D 0 .015 0 .013 0.019 0.008 -0 .001 -0.003 0 .119 0.116 0.113 
F -0 .001 0.003 0.006 0.003 0.007 -0.001 0 .037 0.046 0.027 -0 .011 -0.010 
G -0.004 -0.002 0 .004 0.030 0.041 0 .031 0.066 0 .074 0.062 -0.007 -0 .011 
i -0 .002 0.004 0 .006 0 .003 0 .008 0.006 0.093 0.075 0.027 -0.010 -0 .011 
Plate Blank Subtracted L 1 = 0.059 
7/29/99 2:54 :53 PM Marla Ex 4 
Calibrate On 
Plate Read: 
2:50 PM 7/29/99 
Temp-late for· Fifth ELISA 
- - - :) N i : - -_,
-~ - -- -- -
; 
-- -
i I i ·- - -··---··-- - - - --~1 - j l j <\ !{_~T~ j J ,.. -\. -\. -\- {. ,) i,. ~I ' 
' 
• I "I.) 
I I l i 
l ~:~~ . <! ~ l ~ l ~ l ~ l ~ l ~ l 







- - - ~ -
_()-- - - - ~ 
' 
vi;> ~ 
I --- - - - ~ -











































~ ' '.\I ! ~ \~ ~ ! i 
l - . ! \ - \ . i ! ! 
I 
I i I ~ \. •l 
~~ I 
I 
~- i \~'-) I ~ 
i I i \ ""' 
I 
! I I - . . 
~ ~~~ ~-\-. 
I 
I • 
I ! ! 
i i [ I 
~ ~ 




















, _-\t)_~_ ... _&_- _¢ _____ ~__..;. ___ ...i---__._ _ __;..__~_ ~ 
.;;59 
"'J 
~ ~ ~- ~~ ~ Pi) I ':::t- Q-< ~ <:)'°' Q~ - " -
! 








~ - ~ '(( . 
.. 
' ~" ~~ <:5 -- - -: 
I 
~ ..... 
~ C <f tj~ ~ I ~ 
""'( ~ d ';:J. \j l'O t".J ~ ~ 
-~ -t- ~~ i_ ~ I -- i 
Results for Fifth ELISA, Columns 1,4,7 (read with 
alternate conjugate). 
t1 I 
(_{),Oft,{ /lD.- ({ l 
45 37 246 
80 43 57 
65 45 95 _ 
76 40 124 
41 42 81 
49 44 107 
53 68 46 
128 40 58 
Resu:ltsfor Fifth ELISA 7/26/99 
(}y'(f E h) PLAT {5_ 
1,Ari..:rtv 6 Dr 6 
SOFTmax® PRO Default Protocol w/ l<.Je...A/$ +o o,., A-c 4c,,.... 
Overview ~. &ri · u~~ 
This basic protocol is a starting point for creating your own protocol/ data files. ~1:\'is file 
contains the groups Standard, Unknowns, and Blank. -(Additional groups can be added using 
New ... from the template dialog group menu.) The Standards are plotted -tm a Standard Curve. 
The Unknowns are interpolated from the linear fit of the Standard Curve and the calculated 
concentrations are shown in the unknowns group table. 
This file can be modified and saved as_a new protocol file for future use. From the File menu 
select Save As .... In the "Save This Document As" type box, enter a name for the protocol file. 
Click on the Protocol File radio button. Choose Save. 
Assay type: 
Number of plates: 
Endpoint read at 405 nm. 
1 












Raw Data Reduction Parameters 
Wavelength combination: Ll 
Subtract plate blank: Off 
Dat{! Di~pla~ OptiQn 
Option: RawOD 
Plate#1 
2 3 4 5 6 7 
-0. 58 1~252 0 .009 0.008 -0. 58 
8 9 1 0 
0.138 
1 1 1 2 
IA 
B -0 . 58 0 .070 0 .003 0.001 -0. 58 0.050 
IC 
Calibrate On 
-0 . 58 0.084 0 .004 0.008 -0. 58 0 .057 
D -0 . 58 0 .067 0 .003 0.003 -0. 58 0.154 
IE -0. 58 0.050 0.001 0.001 -0 . 0.017 
F -0. 58 0.000 0 .004 0 .004 -0. 0.104 0 .349 -0.001 
G -0. 58 0 .004 0 .021 0.030 -0. 0.039 0.039 
i -0 . 58 0.078 0 .047 0 .008 -0. 58 ' 0 .399 
Plate Blank Subtracted L 1 = 0.05775 
Discussion: Obviously, the returned results were not what was expected. Potential 
reasons for the apparent random nature of the data would be the instability of M. avium 
DNA, nonspecific binding due to the 'wobble' effect of having the variable region of the 
capture probe at the end adjacent to the reporter probe (e.g. the strand could have been 
'bent' and any capture probe could bind irrespective of the actual mutation), or some other 
unknown factor in the behavior of MAC DNA under these conditions. Additional 
experiments are needed to determine the appropriateness of this technique for use with M. 
avium. Although this technique holds promise for a quick, clear method of determining 
antibiotic resistance, serious attention must be paid to adapting its conditions to a new 
substrate without losing its accuracy. 
Appendix 1 
Illustrations and Tables 
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3. Estimated Incidence of TB: Top 22 Countries 
Table 4, Estimated incidence of TB: top 22 countri.es, 1997 
Estimated incidence Estimatr.d incidence 
all cases ss+ cases Cumulative 
Population x ----~----- - --- ----- --- --------- incidence 
Country 1000 (1997) thousands rate/10' thousands rate/10' (%) 
........ _, .. ____________ _ ...... ____ ...... ·--·--·-·--·· .. ··-··· .......... ............................. ...... ___ ., 
India 960 178 1 799 187 805 84 23 
China 1 243 738 1 402 113 630 51 40 
Indonesia 204 323 583 205· 262 128 48 
Bangladesh 122 013 300 · 246 135 111 51 
PIJkistan 143 831 261 181 117 81 55 
Nigeria 118 369 253 214 110 93 58 
Philippines 70 724 219 310* 99 139 60 
South Africa 43 336 170 392' 69 159 63 
Ethiopia (Fed. Dem. Rep. of) 60148 156 260* 66 109 65 
Viet Nam 76 548 145 189 65 85 66 
Russian Federation 147 708 156 106 70 47 68 
Congo .(Democratic Rep.) 48040 127 263* 54 112 70 
Brazil 163 132 122 75 54 33 71 
Tanzania (United Rep. of) 31 507 97 308* 40 127 73 
Kenya 28 414 84 297' 35 122 74 
Thailand 59 159 84 142 37 63 75 
Myanmar 46 765 80 171 36 71 76 
Arghanistan 22 132 74 333• 33 150 77 
Uganda 20 791 66 320* 27 128 78 
Peru 24 367 65 265* 29 119 78 
Zimbabwe 11 682 63 530• 24 207 79 
Cambodia 10 516 57 539• 25 241 80 
--· -- ----···-- -------------- . --···-·· ---------
22 high burden countries total 3 657 421 6 361 174 2 821 77 80 
--- . ----------------------·------ --·-· - --- -------·------·····--·· 
Global total 5 849 389 7 963 136 3 522 60 100 
-··-··--·-·---··---·-·······-·-··-.. ----·-···----·---·-----···- .. --·-···---·-· .. ·--·-··-··-·-·--·--·--·-·-·-··-···-··--· ----·-----·--···---·-···-···-----·--··----··-· ..... .. .• "----·--·· ... _ .. ___ , --
• Estimated Incidence rate """' 250 cases per 100 000 population 
S<xrce: Dye C, Scheelo S. Oolin r. Pathanla Vt. Raviglione MC. Global burden or tuberculosis: estimate!d ihcidooco. p<evalOOce and mo<tanty by cOU1try in 1907. (Submitted 
fa,- p<bllcatlon.) 
4. Structure of- Ethambutol 
CHOH 
CHOH 
5. Etest procedure (AB Biodisk, Sweden) 
1. 
procedure 
The E tesCM a predefined, continuous and 
exponential gradient of antibiotic concentrations, 
is a novel technique for direct quantification of the 
antimicrobial susceptibility of microorganisms. 
1. Inoculation of agar plate ~ ~ 
according to routine practice. "' 
'1-°"e, 
,g1-I') 
2. Application of the E tests ,~~,. 
r.l'> 




3. R·eading of inhibitory concentrations \., 
(IC) and clinical interpretation. ';~~ .. 
:i:~ 
2. 








6. Close up of characteristic Etest Plate (read as 
MlC=0.125µg/l)-. (AB Biodi·sk, Sweden) 
- J 
/ 
7. Sequence of primers and capture probes. 
62843: MAC primer 1 
j 
) CGTAAGGGTGAAGCGGAGAA 
Length: 20 A: 7 G : 9 C: 2 T: 2 MW (kD): 
Cone: 134.6 A260 U/ml (538.2 pmole/ul) M_olar Ext. Coef.: 
State: HPLC Purified; 5' -OH -- Dissolved in 50 ul of Water •. 
62844: MAC primer 2 
~
1
CTTACACTCGCCACCTGATT ' .1 . 1 
'- ;i 'Y 
6.28 
250,100 
Length: . 2 0 A: 4 G: 2 c: 8 T: 6 MW (kD): 5.98 
Cone: 128.1 A260 U/ml (718.9 pmole/ul) Molar Ext. Coef.: 178,200 
State: HPLC Purified; 5' -OH -- Diss 
r 62845: MAC capture probe A 
j; : "-." - GTTACGCGCGGCAGGACGAA 
:0) 
Length : 2 0 A: 5 G: 8 C : 5 T: 2 MW (kD): 6.19 
Cone: 163.6 A260 U/ml (715 prriole/ul) Molar Ext. Coef.: 228,800 
State: HPLC Purified; 5' -biotin -- Dissolved in 50 ul of Water 
62846: MAC capture probe C ,.. 
·, : . ~ -GTTACGCGCGGCAGGACGAC. 
Length: 20 A:4 G:8 C:6 T:2 MW(kD): 6.16 
Cone: 125.3 A260 U/ml (564.4 pmole/ul) Molar Ext. Coef.: 222,000 
State: HPLC Purified; 5' -biotin -- Dissolved in 50 ul of Water 
62847: MAC capture probe G 
8 · =>.; ,..-GTTACGCGCGGCAGGACGAG 
Length: 20 A:4 G:9 C:5 T:2 MW(kD): 6.20 
Cone: 155.5 A260 U/ml (677 pmole/ul) Molar Ext. Coef.: 229,700 
State: HPLC Purified; 5' -biotin -- Dissolved in 50 ul of Water 
8. . Sequence of capture and reporter probes. 
6 2848: MAC capture probe T 
· - ·· - GTTACGCGCGGCAGGACGAT 
Length: 2 0 A: 4 G : 8 C : 5 T: 3 MW (kD): 6.18 
Cone: 161.2 A260 U/ml (724.2 pmole/ul) Molar Ext. Coef .: 222,600 
State : HPLC Purified; 5' -biotin -- Dissolved in 50 ul of Water 
62849: MAC reporter probe 
.. . ·, . · '.-AAGACCCCGGGACCTTCACT·· - Si "' .:. , • "" ,,... ,.;f" fJ 
) 
Length: 20 A: 5 G: 4 c: 8 T: 3 MW (kD): 
Cone: 64.5 A260 U/ml (324.8 pmole/ul) Molar Ext. Coef.: 
State: HPLC Purified; 5' -P03 -- Dissolved in 50 ul of Water 
6.04 
198,600 
9. Section of Mycobacterium avium genome with 
primers indicated. 
23smac.txt 
• s eq: 23savium 
II 
1 tgcggttgga tcacctcctt 
61 cgagccgtga ggggttcccg 
121 tgccagacac actattgggc 
181 tcttggtggt ggggtgtggt 
241 gcatggtctt ggtggccggc 
301 taagtaagtg tttaagggcg 
361 gggaggctgc gatatgcctc 
421 tgggggaacc cagcacgagt 
481 ggtaacgcgg ggaagtgaaa 
541 gtcagtagtg gcgagcgaac 
601 gttgtgtgtg cggggttgtg 
661 agaaagtgtc gtggttagcg 
721 ggtacgcgaa aacccggcac 
781 atctgctgtg aatctgccgg 
841 cggattagta ccgtgaggga 
901 aaaccgtgtg cctacaatcc 
961 aatgagcctg cgagtcaggg 
1021 aagcgagtct gaatagggcg 
1081 cggagtgatc tacccatggc 
1141 cacttaggtt gaagactgag 
1201 cgtgatagct ggttctcccc 
1261 ggtagagcta ctggatggcc 
1321 atgccgtggt gtaaaagcgt 
1381 ggaaacagcc cagatcgccg 
1441 tagtcgcaga gacaaccagg 
1501 tagctcactg gtcaagtgat 
1561 agccgcggca cattcatctt 
1621 agctccgggt gaccggtggt 
1681 aggcaagtga gaaccttgcc 
1741 cagggtgagt cgggacctaa 
1801 ttcccgtacc cgtgtatggg 
1861 atcgaccatt ccccttcggg 
1921 tagtcaagca atggggtgac 
1981 aagcccgtag agagcgatag 
2041 ccggttgagg cgaattcggt 
2101 acggcccgta ccccaaacca 
2161 aactatggtt aaggaactcg 
2221 taccgtgaac acccttgcgg 
2281 tgtttactaa aaacacaggt 
2341 gcccggtgct ggaaggttaa 
2401 gccccagtaa acggcggtgg 
2461 taagttccga cctgcacgaa 
2521 cgaaattgca ctacgagtaa 
2581 ccttcacoac aacttggtat 
2641 tgaagcacag acgccagttt 
2701 acacctaacg tcgaaccctt 
2761 ggcggttgcc tcctaaaatg 
2821 ~tcc~a~~t!,l!;;l~c~~a~ ~~ t§a~a~~ 
2881 gacgaaagtc gggactagtg 
2941 aaaaggtacc ccggggataa 
3001 ttggcacctc gatgtcggct 
3061 tgttcgccca ttaaagcggc 
3121 ctatccgccg cgcgcgtcag 
3181 cggacgaacc tctggtatac 
3241 gacaggataa ccgctgaaag 
3301 ccttttagag ggataaggcc 
3361 cagtaatgag tgcagggaac 
t ctaaggagc accacgaaaa gcaccccaac tggtggggtg 
t c tgtagtgg acgggggccg ggtgcgcaac agcaaatgat 
cctgagacaa cactcggtcc gtccgtgtgg agtccctcca 
gtttgagtat tggatagtgg ttgcgagcat ctagatgagc 
gttcatcgaa atgtgtaatt tcttttttaa ctcttgtgtg 
catggtggat gccttggcat cgagagccga tgaaggacgt 
ggggagctgt caaccgagca ttgatccgag gatttccgaa 
gatgtcgtgt tacccgtatc tgaatatata gggtgcggga 
catctcagta cccgtaggag aagaaaacaa ttgtgattcc 
cggaacaggc taaaccgcat gcatggacaa ccgggtaggg 
ggattgatat gtctcagctc tacctggctg aggggtagtc 
gaagtggcct gggacggccc gccgtagacg gtgagagccc 
ctgccttata tcaacacccg agtagcagcg ggcccgtgga 
gaccacccgg taagcctaaa tacttctcga tgaccgatag 
atggtgaaaa gtaccccggg agggagtgaa atagtacctg 
gtcagagcct cctcgtgggg tgatggcgtg ccttttgaag 
acacgtcgcg aggttaaccc gtgcggggta gccgcagcga 
catccccttt ggggtgtagt ggcgtgttct ggacccgaag 
cagggtgaag cgcgggtaag accgcgtgga ggcccgaacc 
gggatgagct gtgggtaggg gtgaaaggcc aatcaaactc 
gaaatgcatt t aggtgcagc gttgcgtggt tcaccacgga 
gatgggccct actaggttac tgacgtcagc caaactccga 
ggcagtgaga cggcggggga taagctccgt acgtcgaaag 
gctaaggccc ctaagcgtgt gctaagtgga aaaggatgtg 
aggttggctt agaagcagcc atccttgaaa gagtgcgtaa 
tatgcgccga taatgtagcg gggctcaagc acaccgccga 
tacggtggat gtgggtaggg gagcgtcccc cattcagcga 
ggagggtggg ggagtgagaa tgcaggcatg agtagcgata 
cgccgtaaga ccaagggttc ctgggccagg ccagtccgcc 
ggcgaggccg acagggtagt cgatggacaa cgggttgata 
cgtccctgat gaatcagcgg tactaaccac ccaaaaccgg 
ggcgtggcga ttcggggctg cgtgggacct tcgctggtag 
gcaggaaggc agccgtacca gtcagtggta atactggggc 
gcaaatccgt cgctcactaa tcctgagagg tgatgcatag 
gatcctctgc tgccaagaaa agcctctagc gagcacatac 
acacaggtgg tcaggtagag aataccaagg cgtacgagat 
gcaaaatgcc cccgtaactt cgggagaagg gggcccggaa 
tgggagcggg attcggccgc agaaaccagt gggtagcgac 
ccgtgcgaag tcgcaagacg atgtatacgg actgacgcct 
gaggacccgt taacccat aa gggtgaaqcq qagaat ttaa 
taactataac catccfii agg tagcgaaatt ccttgtcggg 
tggcgtaacg acttcccaac tgtctcaacc atagactcgg 
agatgctcgt tacgcgcggc aggacqa~a gaccccqqqa 
t ggtgttcgg tacggtttgt gtaggatagg tgggagac tt 
gtgtggagtc gttgttgaaa taccactctg atcgtattgg 
atcgggttca cggacagtgc ctggcgggta gtttaactgg 
taacggaggc gcccaaaggt tccctcaacc tggacggcaa 
cacaagggag cttgactgcg agacttacaa gtcaagcagg 
atccggcacc cccgagtgga aggggtgtca ctcaacggat 
cgggctgatc ttccccaaga gtccatatcg acgggatggt 
cgtcgcatcc tggggctgga gcaggtccca aaggttgggc 
acgcgagctg ggtttagaac gtcgtgagac agttcggtct 
aaacttgagg aaacctgtcc ctagtacgag aggaccggga 
cagttgtccc accaggggca cggctggata gccacgttcg 
catctaagcg ggaaaccttc tccaagatca ggtttc t cac 
ccccgcagac cacgggattg ataggccaga cctggaagct 
tggcactaac tggccgaaag c 
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